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Universitätsmedizin and Deutsches Rheuma-Forschungszentrum, Berlin, Germany; 6Division of Rheumatology, Department of Medicine,
Toronto Western Hospital, University of Toronto, Toronto, Canada; and 7Mount Sinai Hospital, Toronto, Canada
Objective: The European League Against Rheumatism and the American College of
Rheumatology jointly embarked on a new classification criteria for systemic lupus erythema-
tosus (SLE) project. Its first phase involved generation of a broad set of items potentially
useful for classification of SLE. This study was undertaken to add the patient perspective to an
expert Delphi approach and an early patient cohort study. Methods: A national cross-sec-
tional study was conducted. A self-report questionnaire was published in the ‘‘Schmetterling’’
(Butterfly), the quarterly journal of the German SLE patient association. Individuals with
SLE were asked to anonymously complete the questionnaire, which asked for demographic
details, organ manifestations, autoantibodies and symptoms. Results: A total of 339 com-
pleted questionnaires out of 2498 were returned, a response rate of 13.6%; 83.2% reported
they were ANA positive and 81.7% reported joint, 66.1% skin and 33.0% renal involvement.
For the time before and in the first year after their SLE diagnosis, the majority reported
fatigue (89.4%), joint pain (86.7%), photosensitivity (79.4%) and myalgia (76.1%). Of inter-
est, more than half of the patients reported fever as an early symptom (53.7%). Conclusion:
For a Caucasian European SLE patient population, the overall characteristics suggest mean-
ingful representation. While many symptoms were reported as expected, the high percentage
of patients reporting fever and the significant number of patients with unexpected gastrointes-
tinal complaints are of particular interest. These data add to the information on early SLE
symptoms informing the development process of new SLE classification criteria. Lupus
(2018) 27, 1431–1436.
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Introduction
With its high variability in autoantibody-mediated
symptoms, systemic lupus erythematosus (SLE)
may be difficult to classify early in the course of
disease. Of the two sets of SLE classification cri-
teria commonly used today, the Systemic Lupus
International Collaborating Clinics (SLICC) 2012
criteria1 are more sensitive than the 1982 and
revised 1997 American College of Rheumatology
(ACR) criteria,2,3 albeit at the expense of lower spe-
cificity. Despite their advanced sensitivity, even the
SLICC criteria show suboptimal recognition of
patients with early SLE.4 Accordingly, early classi-
fication is one goal of a joint European League
Against Rheumatism (EULAR)/ACR project
aimed at developing even better SLE classification
criteria.
The first phase of this project was designed to
broadly gather potential candidate items. This was
approached with an SLE expert Delphi exercise5
and an international early SLE cohort study.6 It
has been recommended by EULAR to include the
patient perspective in EULAR supported projects.7
Based on the feasibility of previous projects with
the German SLE patient organization Lupus
Erythematodes Selbsthilfegemeinschaft e.V.,8,9 the
SLE classification criteria steering committee decided
to add this additional patient-centered study.
Correspondence to: Nicolai Leuchten, Technische Universität
Dresden, Fetscherstrasse 74, Dresden 01307, Germany.
Email: nicolai.leuchten@uniklinikum-dresden.de
Received 1 December 2017; accepted 17 April 2018
! The Author(s), 2018. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav 10.1177/0961203318776093
Both clinical routine and discussions with the
SLE patient organization resulted in the impression
that SLE patients usually experience the onset and
diagnosis as a critical life event and that memories
of this time remain remarkably accurate.
Accordingly, while patients can only be approached
via the patient organization later in their disease
course, the focus on early disease appeared feasible.
We here accordingly report, to our knowledge,
the first ever approach to directly involve a large
number of patients in the item generation phase of
classification criteria development for any rheum-
atic disease.
Patients and methods
As approved by the local ethics committee, we con-
ducted a cross-sectional survey of German SLE
patients. An anonymous self-report questionnaire
was published in the ‘‘Schmetterling’’ (English
translation: Butterfly), the quarterly journal of the
Lupus Erythematodes Selbsthilfegemeinschaft, the
German SLE patient association. A total of 2498
copies of the questionnaire were mailed with the
quarterly journal to members of the patient associ-
ation. Patients were asked for year of and age at
their initial diagnosis.
The questionnaire included a list of typical organ
manifestations (skin, joints, renal, central nervous
system (CNS), blood count, anti-phospholipid syn-
drome and fibromyalgia) and autoantibodies
(ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB,
anti-Sm, anti-U1RNP and anti-cardiolipin). In
addition, a list of characteristic symptoms
(Raynaud’s, fatigue, fever, joint pain, myalgia,
pleuritic pain, skin bleeding, skin rash, photosensi-
tivity, leg edema and thrombosis) was provided. No
specific definitions were given for any of these
symptoms, but the terms were translated into
simple descriptors (e.g. ‘‘blue/white fingers’’ for
Raynaud’s, ‘‘muscle pain’’ for myalgia, and ‘‘pain
when breathing’’ for pleuritic pain) where possible.
In addition, patients were asked to add additional
symptoms in free text.
For each symptom, boxes were provided to indi-
cate the presence of the symptom before diagnosis,
in the first year of the disease and at the time of
completion of the questionnaire. Patients were
instructed on the questionnaire as follows: ‘‘The
first sheet aims at understanding your organ
involvement. Please do only tick ‘Yes’ if you are
sure that you have (or had) this organ problem
yourself. Likewise, we would ask you to only tick
specific autoantibodies when those have definitely
been tested positive for you. For the symptoms, we
would ask you to tick ‘Yes’ or ‘No’ for now, for the
first year after your SLE diagnosis, and for the time
before the diagnosis of SLE, for each specific symp-
tom or problem. The last page is for symptoms that
are not yet listed.’’ Questionnaires were anonym-
ously completed and mailed to the Technische
Universität Dresden Medical Center. The original
questionnaire and the English translation are avail-
able as Supplement 1 and 2.
To avoid overestimation, the percentages given
throughout the text refer to the number of total
questionnaires that were collected. In Tables 1
to 3 the percentages without the missing data (not
sure, do not wish to answer, or missing ticks) are
given, the denominator corresponding to the total
number of yes or no answers to each question.
Data from the questionnaires were extracted and
analyzed in duplicate by B.M. and N.L. The free
text symptoms were combined and, where ade-
quate, subsumed under broader categories.
Discrepancies where resolved by joint discussion.
Table 2 Percentage of reported organ involvement at any
time
All patients Y/N answer
Joint involvement 81.7 89.9 (308)
Skin involvement 66.1 74.7 (300)
Renal involvement 33.0 39.9 (281)
Blood/bone marrow involvement 26.8 33.3 (273)
Fibromyalgia 21.8 28.5 (260)
CNS involvement 18.6 23.8 (265)
In the ‘‘All patients’’ column the denominator is all 339 patients that
returned the questionnaire. In the ‘‘Y/N answer’’ column the denom-
inator (given in parentheses) is the number of patients that gave yes or
no answers.
CNS: central nervous system.
Table 1 Patient characteristics
All patients SD Y/N answer
Disease duration (mean years) 17.1 10.3
Age at diagnosis (mean years) 36.2 14.0
Female (%) 92.6
ANA positive (%) 83.2 94.6 (298)
Anti-dsDNA positive (%) 53.7 78.4 (232)
Anti-Ro/SSA positive (%) 22.4 42.0 (181)
Anti-cardiolipin positive (%) 16.5 33.9 (165)
Anti-La/SSB positive (%) 13.0 27.0 (163)
In the ‘‘All patients’’ column the denominator is all 339 patients that
returned the questionnaire. In the ‘‘Y/N answer’’ column the denom-
inator (given in parentheses) is the number of patients that gave yes or
no answers.
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Descriptive statistics were performed using
Microsoft Excel 2010 and GraphPad Prism 5.01.
Questionnaires were included in the analysis when
mailed within six months after publication.
Results
A total of 339 patient questionnaires were anonym-
ously completed and sent to the Technische
Universität Dresden Medical Center. This equates
to a response rate of 13.6%. Of the respondents,
92.6% were female. The respondents’ mean age at
diagnosis was 36.2 years, and their mean disease
duration was 17.1 years. Patient characteristics
are shown in Table 1.
Most patients (83.2%) reported to be ANA
positive. The presence of antibodies against
dsDNA, Ro/SSA and La/SSB was reported by
53.7%, 22.4% and 13.0%, respectively. Anti-
cardiolipin antibodies were only reported positive
by 16.5% of the participants. The organ systems
most commonly involved were joints, skin and kid-
neys at frequencies of 81.7%, 66.1% and 33.0%,
respectively, and 18.6% reported CNS involvement
(Table 2). In addition, 21.8% of the participants
reported that they had (secondary) fibromyalgia.
In the check box list of symptoms in the early
phase of the disease the highest percentages of
reported symptoms were fatigue (89.4%), joint
pain (86.7%), photosensitivity (79.4%), myalgia
(76.1%) and skin rash (70.5%). All of the check
box symptoms were reported at least numerically
higher for the early phase of the disease, that is
before or in the year after diagnosis, than for the
time of the questionnaire (Table 3). Most check box
symptoms were also reported more frequently in
the first year after diagnosis than before diagnosis,
except for fever and thrombosis. Notably, the high-
est differences between early and late phase
symptoms were found for fever and pneumonia
(Figure 1(a)), which were both reported around
three times more frequently in early disease.
Likewise associated with early disease were throm-
bosis, skin rash, alopecia and pleuritic pain. In
contrast, skin bleeding, Raynaud’s, photosensitiv-
ity, fatigue and leg edema were reported with essen-
tially unchanged frequency for late disease,
defined as >90% of the frequency around diagnosis
(Figure 1(b)).
As expected, free text symptoms were reported
with a far lower frequency than check box symp-
toms. Free text symptoms actively volunteered by
at least five patients are listed in Table 4. The high-
est frequencies for early disease were reported for
headache/migraine, sicca symptoms and depres-
sion/mood disorder at 10.0%, 9.7% and 8.6%,
respectively. The reported frequencies for head-
ache/migraine decreased to 7.7% in late disease,
while sicca symptoms increased to 15.9%.
Depression/mood disorder was reported at 5.2 %
before diagnosis and at a consistent frequency of
around 8% from diagnosis throughout late disease.
Diarrhea/abdominal pain were reported at rela-
tively stable frequencies of close to 5% (Table 4).
Susceptibility to infections was also associated with
early disease (3.2% versus 1.5%). In contrast
Table 3 Frequency of symptoms in percent before diagnosis, at the time of diagnosis and at the time of questionnaire completion
Reported symptoms (%)
Before diagnosis At diagnosis Before or at diagnosis Time of questionnaire
All patients Y/N answer All patients Y/N answer All patients Y/N answer All patients Y/N answer
Fatigue 73.2 74.7 (332) 85.8 88.2 (330) 89.4 89.9 (337) 82.9 85.4 (329)
Joint pain 74.3 75.4 (334) 80.2 82.2 (331) 86.7 88.8 (334) 71.4 72.9 (332)
Photosensitivity 63.7 64.7 (334) 75.2 77.7 (328) 79.4 80.3 (335) 74.6 77.1 (328)
Myalgia 62.2 63.6 (332) 69.0 71.8 (326) 76.1 77.6 (331) 66.1 69.1 (324)
Skin rash 59.0 60.1 (333) 59.9 63.0 (322) 70.5 72.9 (328) 44.0 46.3 (322)
Fever 44.0 45.3 (329) 39.2 41.2 (323) 53.7 56.2 (324) 13.9 14.5 (324)
Raynaud’s 39.2 40.3 (330) 48.7 50.6 (326) 51.9 53.7 (328) 49.3 50.9 (328)
Alopecia 31.0 31.8 (330) 46.3 48.3 (325) 50.7 52.8 (326) 37.8 39.5 (324)
Shortness of breath 28.0 29.4 (323) 31.3 33.9 (313) 36.6 39.5 (314) 32.7 34.3 (324)
Leg edema 20.9 21.6 (329) 27.4 28.9 (322) 31.0 32.7 (321) 28.6 30.4 (319)
Skin bleeding 18.0 18.8 (325) 22.4 24.2 (314) 25.4 27.2 (316) 24.8 26.5 (317)
Pleurisy 16.2 16.8 (327) 17.7 18.8 (319) 23.3 24.5 (322) 18.6 19.9 (316)
Pneumonia 13.0 13.5 (326) 13.3 14.2 (317) 21.8 23.3 (318) 7.4 7.8 (319)
Thrombosis 13.9 14.2 (331) 10.6 11.1 (323) 18.0 18.8 (325) 9.1 9.6 (322)
In the ‘‘All patients’’ column the denominator is all 339 patients that returned the questionnaire. In the ‘‘Y/N answer’’ column the denominator
(given in parentheses) is the number of patients that gave yes or no answers.
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sicca symptoms (9.7% versus 15.9%) and polyneur-
opathy/paresthesia (4.7% versus 7.1%) were at
least 50% more common in late disease.
Discussion
The overall patient characteristics are consistent
with a Caucasian European patient population.
The percentage of female patients and the age at
diagnosis are similar to published cohorts.6,10,11
The participants had mostly long-standing disease
with mean disease duration of 17.1 years. The
prevalence of anti-dsDNA antibodies and anti-
Ro/SSA antibodies was in the expected range.
Although in a systematic literature review, 98%
of SLE patients are positive for ANA on HEp-2
cells,12 the fact that more than 4 in 5 patients
(83.2%) were certain to be ANA positive is likewise
reassuring. Still, underreporting of laboratory
values (without symptoms) would be expected.
Indeed, blood or bone marrow involvement was
reported by 26.8% in this study only, as compared
to 74% leukopenia in the international early lupus
cohort study within this project,13 80% in the
Spanish Society of Rheumatology SLE registry
(RELESSER) cohort and 59% in the ACR 1982
cohort.3,11
Arthritis/joint involvement and renal involve-
ment were reported at a very similar percentage
to that in the compared cohorts. In the ACR
1982 cohort, there was a higher (51%) rate of
renal involvement.3 This may indicate a cohort
enriched for nephritis (or more severe SLE), an
influence of different definitions of nephritis (pro-
teinuria >500mg/d in the ACR cohort), or even a
change in the prevalence of lupus nephritis since the
1980s. Photosensitivity was reported at 79.4% early
and at 74.6% late in this study, a notably higher
percentage than in the European Working Party on
SLE Euro-Lupus cohort, the ACR 1982 cohort and
the RELESSER cohort.3,10,11 This is of note since
the definition of photosensitivity in the compared
cohorts likewise relies on self-report. Skin involve-
ment was reported at 66.1%, similar to the SLICC
cohort at 65.2%.1 Fever was reported in the Euro-
Lupus cohort only, but at a relatively high fre-
quency of 52.4%.10 In the current study, fever
was reported as an early phase symptom by
Figure 1 Prevalence of predefined symptoms reported for early and late disease. (a) Symptoms reported more frequently for early
disease; and (b) Symptoms reported for late disease at >90% of the frequency of early disease.
Table 4 Free text symptoms beyond those predefined in the
questionnaire
Additional reported
symptoms n (%)
Before
diagnosis
At
diagnosis
Before or
at diagnosis
Time of
questionnaire
Headache/migraine 27 (8.0) 29 (8.6) 34 (10.0) 26 (7.7)
Sicca symptoms 17 (5.0) 32 (9.4) 33 (9.7) 54 (15.9)
Depression/
mood disorder
19 (5.2) 28 (8.3) 29 (8.6) 27 (8.0)
Cognitive impairment 13 (3.8) 23 (6.8) 25 (7.4) 24 (7.1)
Dizziness/vertigo 12 (3.5) 19 (5.6) 20 (5.9) 18 (5.3)
Diarrhea/abdominal pain 13 (3.8) 16 (4.7) 18 (5.3) 14 (4.1)
Polyneuropathy/
paresthesia
9 (2.7) 16 (4.7) 16 (4.7) 24 (7.1)
Mucositis/ulcers 11 (3.2) 12 (3.5) 14 (4.1) 16 (4.7)
Sleep disturbance 8 (2.4) 12 (3.5) 13 (3.8) 17 (5.0)
Susceptibility to infections 9 (2.7) 11 (3.2) 11 (3.2) 5 (1.5)
Pericarditis/
pericardial effusion
8 (2.4) 11 (3.2) 10 (2.9) 4 (1.2)
Exercise intolerance 4 (1.2) 9 (2.7) 9 (2.7) 11 (3.2)
Easy bruising 4 (1.2) 5 (1.5) 9 (2.7) 10 (2.9)
Weight loss 6 (1.8) 4 (1.2) 8 (2.4) 4 (1.2)
Lymphadenopathy 8 (2.4) 5 (1.5) 8 (2.4) 4 (1.2)
Tinnitus 3 (0.9) 6 (1.8) 6 (1.8) 11 (3.2)
Conjunctivitis 6 (1.8) 4 (1.2) 6 (1.8) 6 (1.8)
Nausea 6 (1.8) 5 (1.5) 6 (1.8) 3 (0.9)
Pulmonary embolism 3 (0.9) 3 (0.9) 5 (1.5) 4 (1.2)
Seizures 4 (1.2) 5 (1.5) 5 (1.5) 3 (0.9)
Please note that these patients volunteered these complaints without
being reminded of such a possibility, which presumably led to relative
underrepresentation.
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almost the same proportion (53.7%) of partici-
pants. Alopecia was reported for the early phase
by 50.7% of the participants comparably to the
ACR 1982 cohort (55.9%) but more frequent
than in the RELESSER or SLICC cohort (see
Table 5).1,3,10 The frequency of pneumonia before
or at diagnosis was possibly overreported with a
frequency of 21.8%. Nonetheless, the frequency
for the first year after diagnosis is at 13.3%, com-
parable to published cohorts.14,15
Many of the inflammatory manifestations of
SLE are known to decrease over time.14 This is in
part attributed to treatment effects. Such reduction
in inflammatory symptoms is also evident from the
present study, as most symptoms were reported
with lower frequency at the time of the question-
naire. Among the symptoms less commonly present
over time were rash, alopecia, joint pain and myal-
gia. While fever may also be due to infections
associated with high level immunosuppression,16
non-infectious fever apparently is quite common
in early SLE, and may indeed be a distinguishing
feature.6 As a possible limitation to this finding,
fever might be overreported by patients since no
specific definition was given and no objective
method was required.
These data accordingly suggest face validity of
the patients’ memory and mostly correct patient
attribution of their symptoms to SLE. This may
have been aided by the fact that patients organized
in SLE patient groups are particularly well-informed
and may have reflected on their symptoms quite
early in their disease. Under these circumstances, it
is interesting that approximately 5% of the patients
volunteered gastrointestinal complaints, which were
not expected and therefore not asked for. None of
the published SLE cohorts compared in Table 5
included gastrointestinal symptoms. In combination
with an earlier patient Delphi similarly showing
gastrointestinal complaints in SLE patients,9 these
yet unclear symptoms should be placed on the
scientific agenda.
Taken together, this first attempt to directly
include patient reported symptoms into an SLE
classification criteria approach was successful in
providing relevant data on candidate criteria
items relevant for early SLE. The majority of symp-
toms and manifestations recalled by the SLE
patients in this study were in line with published
literature. Importantly, however, the frequencies
of fever and gastrointestinal complaints were unex-
pectedly high and need consideration. Non-
infectious fevers are apparently quite common in
early active SLE, and may be a useful SLE
criterion.
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